← board
YBGJ
distress 6/10 · elevated risk$0.01-6%today-90% from 52w high
Revenue
pre-revenue
Liquidity
$0M
Runway
0.0 yrs
Shares 1y
0%
Price & events
+12.9% over 6M
CatalystRating changeDilutionFinancingdashed = today
-6.0%
1D
-6.0%
1W
+100.0%
1M
+40.0%
3M
+12.9%
6M
-89.2%
1Y
-91.2%
2Y
—
5Y
-96.9%
All
Overview
- Market Cap
- $2.39M
- Volume
- 2.00K
- 52 Week Range
- $0.01 – $0.14
- Total Shares
- 170.42M
- Float Shares
- 22.11M
- % Held by Insiders
- 91.21%
- % Held by Institutions
- 0.00%
- RVOL
- 0.30x
- Beta
- 0.67
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 0
- No catalyst news yet.
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: 170,416,343 · 0 offerings/1y · 1 PIPEs
- 2025-07-258-Kprivate_placement
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.